EMEA-001045-PIP01-10-M02 - paediatric investigation plan
sarilumab
PIPHuman
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695
E-mail: contact-us@sanofi.com
P/0144/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sarilumab (Kevzara) (EMEA-001045-PIP01-10-M02)